Canicol

Quick links to important sections

Canicol

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Canicol

Quick Facts

Property Description
Active ingredient Thiamphenicol
Form Crystalline powder, formulated for injection and oral use
Pharmacological class Amphenicols (Antibiotic/Antimicrobial)
General purpose Management of bacterial infections
Origin Semisynthetic derivative (of Chloramphenicol)

Canicol: Identity and Pharmacological Classification

Canicol is a pharmaceutical product primarily known for its single active ingredient, Thiamphenicol, which is classified as a broad-spectrum antimicrobial agent. This medication belongs to the Amphenicols group, specifically designated by the Anatomical Therapeutic Chemical (ATC) code J01BA02. This classification defines its role as a systemic antibiotic used to manage infections. Thiamphenicol is clinically recognized for its effectiveness against a wide range of susceptible microorganisms, supporting its use in treating bacterial illnesses.

The general purpose of this type of medicine is the containment of existing bacterial infections. Thiamphenicol is a prescription-only drug designed for systemic delivery to suppress the proliferation of various Gram-positive and Gram-negative bacteria.

Thiamphenicol: Composition, Origin, and Forms

The therapeutic effect of Canicol is derived from the compound Thiamphenicol, a semisynthetic derivative of the classic antibiotic chloramphenicol. The substitution of the nitro group in chloramphenicol with a methyl-sulfonyl group differentiates its chemical structure. This specific modification is a key differentiating factor, making the compound suitable for specific clinical applications.

The active substance is manufactured from a crystalline powder and formulated for systemic use, including preparations for oral ingestion and parenteral routes. In some variations, the active moiety is supplied as a prodrug, such as Thiamphenicol glycinate acetylcysteine, which is designed to release the active Thiamphenicol in vivo to exert its primary bacteriostatic effect. The substance’s main function is to inhibit the growth of targeted bacteria. Canicol is positioned as a reliable option where its distinct pharmacological properties are medically advantageous.

What side effects are possible with Canicol?

Possible Side Effects and Safety Information

The safety profile of Canicol (Thiamphenicol) is primarily characterized by the officially documented risk of haematological disorders associated with the Amphenicol class of antibiotics. Regulatory documents classify potential adverse reactions based on System-Organ Classes (SOC) and frequency of occurrence.

Documented Adverse Reactions by System-Organ Class

The most serious regulatory concern involves Blood and lymphatic system disorders, which include rare but serious effects such as aplastic anaemia, bone marrow suppression, agranulocytosis, and pancytopenia. Other systems affected, as documented in regulatory safety tables, include Gastrointestinal disorders (e.g., nausea, vomiting, diarrhoea) and Nervous system disorders (e.g., headache, peripheral neuritis).

Classification Examples of Officially Listed Effects
Serious / Very Rare Aplastic anaemia, Bone marrow failure, Neonatal Grey syndrome
Common / Uncommon Nausea, Vomiting, Diarrhoea, Headache, Urticaria

Safety Considerations and Restrictions

Official safety labeling addresses specific population risks. Neonates and premature infants are subject to a specific warning concerning the potential for developing Neonatal Grey syndrome due to reduced drug metabolism. Caution is also noted for patients with renal impairment, as reduced kidney function can prolong the drug's half-life, potentially leading to accumulation.

Furthermore, regulatory safety documentation emphasizes that the risk of certain blood disorders may be delayed, occurring weeks or months after treatment cessation. For this reason, official prescribing information restricts the use of repeated or prolonged courses. The medication is officially contraindicated in individuals with a known history of blood dyscrasias.

Overdose and Emergency Response

Overdose and when to seek help

The information below outlines the officially documented presentations of overdose and the mandatory emergency actions required by regulatory authorities for Canicol (Thiamphenicol).

Officially Documented Overdose Presentations

High or excessive cumulative exposure is associated with significant haematological toxicity. Documented manifestations may include a dose-related suppression of blood cell production, resulting in decreased white blood cell count (Leukopenia) and decreased erythrocyte count (Erythropenia). Severe high-dose exposure carries the risk of bone marrow suppression leading to potentially fatal pancytopenia (a deficiency in all cellular blood components), which is recognized as a life-threatening outcome.

When to Seek Immediate Medical Help

Regulators mandate that immediate medical attention must be sought for any suspected overdose or accidental ingestion. A doctor must be consulted if the patient feels unwell following exposure. Management procedures officially prescribed focus on supportive care due to the lack of a specific antidote; the standard procedure is to treat symptomatically.

Special Considerations

Intensive haematological monitoring (blood cell counts) is required during the management of high-dose exposures to detect and manage the onset of blood dyscrasias. The official regulatory profile notes an increased risk for severe dose-related effects in patients with renal failure and in the elderly population.

Therapeutic Uses of Canicol

What Canicol Treats: Main Uses and Benefits

Canicol is used in situations involving certain distressing symptoms associated with bacterial conditions, including those such as Typhoid and Paratyphoid Fever. It is applied in clinical settings that involve acute or unstable symptom patterns, including conditions marked by increased physiological stress. The medication is commonly used to help with symptoms related to systemic imbalance, such as fever and general malaise. This supports the patient during difficult episodes by easing distress and contributing to improved day-to-day comfort during symptomatic periods.

The medication is relevant for use in conditions that may include respiratory tract infections, genitourinary conditions such as chancroid and Pelvic Inflammatory Disease (PID), and systemic issues.

Support for Acute Symptom Burdens

The medication is commonly used across conditions characterized by periods of heightened symptoms in the respiratory tract, including acute infections like tracheobronchitis or when an underlying condition, such as chronic bronchitis, experiences a sudden exacerbation. It is applied in scenarios where additional management of discomfort is required, particularly when symptoms interfere with daily functioning. Its use is relevant for easing symptoms that interfere with daily functioning, such as cough, and may assist with clearing the airways, contributing to easing the overall symptom load.


Quick Fact: Symptom Support in Airway Conditions

Symptom Category Therapeutic Benefit
Systemic Symptoms Supports easing distress from fever and malaise.
Airway Symptoms Helps manage cough and supports clearing of airways.
Acute Periods Applied during periods of heightened discomfort or exacerbation.

Eligibility and Restrictions for Use

Who Can and Cannot Use Canicol?

The eligibility for Canicol (Thiamphenicol) is strictly defined by official regulatory documentation, focusing on population-specific contraindications and restrictions.

Absolute Contraindications: The medicine must not be used in individuals with a known hypersensitivity to Thiamphenicol or other Amphenicol antibiotics. Use is strictly prohibited for patients with severe renal impairment or severe hepatic impairment, as well as those with a history of bone marrow disorders or depression.

Age and Restricted Populations: While generally approved for adults and older children, specific restrictions apply to the youngest populations. Use is not recommended or is subject to special caution in premature infants and newborn babies (under four weeks) due to metabolic immaturity.

Conditional Use and Monitoring: Patients with non-severe renal impairment are restricted to conditional use requiring mandatory dose adjustments. Furthermore, any prolonged course of treatment necessitates regulatory-mandated periodic blood examinations to ensure eligibility is maintained.

Pregnancy and Lactation: Canicol is not recommended or is contraindicated during pregnancy and lactation (breastfeeding), as documented in official prescribing information.

What should I know about interactions with other medicines?

Canicol Interactions with other medicines and products

Official regulatory documents describe specific limitations and requirements when Canicol is used concurrently with other medicines or products, primarily based on how co-administered substances affect Canicol's plasma concentrations. These constraints ensure safe use by managing potential increases or decreases in drug exposure.

Key interaction domains involve substances that affect the metabolic pathway mediated by the CYP3A4 enzyme or certain drug transporters. Strong inhibitors of CYP3A4 require a defined maximum dose constraint for Canicol, and the concomitant use of Canicol with the combination of Tipranavir plus Ritonavir should be avoided entirely.

Conversely, when co-administered with the CYP3A4 inducer Rifampin, official guidance specifies that both agents must be given simultaneously to address the reduced exposure of Canicol. Separate interaction profiles are documented for other lipid-modifying agents, including fibric acid derivatives like Gemfibrozil and lipid-modifying doses of niacin.

Canicol may also affect the levels of other medications. When co-administered with Digoxin, appropriate monitoring of Digoxin plasma levels is required upon initiation. Additionally, co-administration with oral contraceptives containing ethinyl estradiol and norethindrone can increase the exposure of these hormonal components, which should be considered.

Mechanism of Action

Interference with Bacterial Protein Production

The primary mechanism of Canicol (Thiamphenicol) involves the inhibition of bacterial growth by targeting the bacterial 70S ribosome, specifically by binding to the 50S ribosomal subunit. This interaction physically blocks the peptidyl transferase center, an enzyme required for linking amino acids together to form proteins. The resulting blockade arrests the creation of essential microbial proteins, leading to a bacteriostatic effect that halts bacterial proliferation.


Selective Molecular Targeting

A crucial aspect of this mechanism is the drug's selective toxicity, exhibiting a greater affinity for the prokaryotic 70S ribosome than the human eukaryotic 80S ribosome, a property achieved by the molecule's differential affinity for prokaryotic ribosomes. Furthermore, the molecule's unique structure is not recognized by the common bacterial defense enzyme, Chloramphenicol Acetyltransferase (CAT), which is typically involved in the inactivation of related molecules. This differential affinity and chemical structure allow the molecule to induce and maintain the arrest of bacterial growth.

Dosage and Administration Information

Official Administration Guidelines

Canicol (Thiamphenicol) is administered through two officially approved methods: Oral ingestion and the Parenteral route, which encompasses both Intravenous (IV) and Intramuscular (IM) injection. The preparation for injection is frequently supplied as a prodrug (e.g., thiamphenicol glycinate), a compound that requires reconstitution into a solution and subsequent conversion within the body to release the active substance.

Dosing and Administration Patterns

Official usage dictates adherence to gram-level quantities of the active substance, structured as short-course or intermittent regimens. For some labeled indications, the prescribed schedule is defined by a single high dose, such as 2.5 g when administered orally. The administration pattern may involve a single, one-time dose or an intermittent schedule requiring a follow-up dose after a defined time interval. Parenteral administration follows a distinct dosage scale and is used when rapid systemic exposure is required or when oral ingestion is not feasible.

For oral forms, the label permits intake with or without food. There are no consistently stated high-level adjustments for specific populations, such as those with renal or hepatic impairment, in the general technical descriptions of the medication.

Recent Clinical Evidence

Research evidence / Overview of studies for Canicol

Canicol (Thiamphenicol) has been evaluated in research as an antimicrobial agent in various clinical settings. The research base includes controlled clinical trials, retrospective studies, and extensive laboratory data, but the certainty and consistency of findings evidence quality varies across studies. This overview details what the existing research has explored and where the limitations lie.

Evidence for Use in Respiratory Tract Infections

Research has explored the use of Canicol, often in specific prodrug formulations, in conditions characterized by fluctuating or episodic manifestations such as acute infections or flare-ups of chronic bronchitis. These studies were studied for their relevance in trials assessing short-term or episodic symptom patterns.

The studies were studied for outcomes related to physical discomfort, such as changes in the frequency and intensity of cough. The observed populations included adults and children with defined bacterial infections. What remains uncertain is the picture regarding long-term clinical changes; long-term effects are not fully established because follow-up durations were limited to the short-term course of treatment.

Evidence for Use in Genitourinary Conditions and Enteric Fever

Research has explored the use of Canicol in conditions like Nongonococcal Urethritis (NGU) and systemic infections such as Typhoid and Paratyphoid Fever. This was evaluated in Randomized Controlled Trials (RCTs) and Comparative Studies examining different antibiotic regimens.

These studies were studied for their role in assessing both outcomes related to systemic or functional imbalance (like fever or malaise) and specific microbiological clearance. The evidence quality varies across studies; many trials are of a historical design, meaning that bacterial resistance patterns may have changed over time since the studies were conducted. Comparative evidence is lacking against the currently preferred first-line treatments for enteric fever.

The Role of Laboratory and Susceptibility Data (Non-Clinical Evidence)

Research describes the medicine's activity through extensive laboratory-based susceptibility studies (in vitro data). These findings establish the defined microbiological parameters (MIC), which are used in research to describe the drug as a broad-spectrum agent. Laboratory results describe group patterns, not personal outcomes, and in vitro data alone cannot predict clinical efficacy without supporting human clinical trials.

Frequently Asked Questions (FAQ)

Common questions about Canicol (FAQ)


Q: How long does Canicol take to start working?

A: Research and studies examining Canicol have primarily focused on outcomes related to short-term or episodic symptom patterns and short-term courses of treatment for acute infections. Official information suggests that effects are typically expected within the initial period of use, aligning with its role in short-course regimens.


Q: Can I take Canicol if I am already taking supplements?

A: Official regulatory documents specifically describe interaction profiles for Canicol when co-administered with certain medications, including lipid-modifying agents such as specific doses of niacin and fibric acid derivatives. This regulatory information assists healthcare providers in considering the concurrent use of these substances and managing potential changes in the drug's activity.


Q: Are the side effects of Canicol permanent?

A: Official safety documentation emphasizes that the risk of certain serious adverse reactions, specifically blood disorders like bone marrow suppression, may be delayed. These effects have been documented to potentially occur weeks or months after treatment has been stopped.


Q: Is Canicol safe to use long-term?

A: Official prescribing information and safety documentation restricts the use of repeated or prolonged courses of Canicol. This restriction is in place because the medicine is associated with a documented risk of certain serious blood and lymphatic system disorders. Follow-up durations in research were generally limited to the short-term course of treatment.


Q: Does Canicol interact with birth control pills?

A: Regulatory documents describe that the co-administration of Canicol with oral contraceptives containing ethinyl estradiol and norethindrone can increase the exposure of these hormonal components. This information is included in regulatory documents for consideration when assessing concurrent use.


Q: What is the expected timeline for improvement when taking Canicol?

A: Clinical studies evaluated outcomes related to the management of acute symptoms, such as changes in the frequency of cough and systemic symptoms like fever. Studies focused on outcomes during the short-term course of treatment, which is the time frame used to assess changes in symptoms based on the limited clinical follow-up data.


Q: Is Canicol the same kind of medicine as [similar common drug]?

A: Canicol (Thiamphenicol) is classified as an Amphenicol antibiotic used to manage bacterial infections. The medicine is structurally known as a semisynthetic derivative of the classic antibiotic chloramphenicol, with a specific chemical difference.


Q: Does Canicol make you sleepy or tired?

A: Official safety documentation notes side effects classified as Nervous system disorders, such as headache and peripheral neuritis. If a patient experiences feelings like tiredness or sleepiness, it may be associated with potential effects on the nervous system.


Q: Can Canicol be used by teenagers?

A: Official eligibility documentation for Canicol permits use by adults and older children. While use is restricted or not recommended for the youngest populations, such as premature infants, specific regulatory information regarding use in the teenager population is provided within the full prescribing details.


Q: Is there any research that links Canicol to kidney problems?

A: Official regulatory documents explicitly specify that Canicol is contraindicated in individuals with severe renal impairment (severe kidney problems). Furthermore, caution is required for patients with non-severe renal impairment, which necessitates mandatory dose adjustments.


Q: Does Canicol affect my ability to drive?

A: The official safety documentation lists side effects that affect the nervous system, such as headache and peripheral neuritis. General regulatory guidance related to nervous system side effects typically cautions against activities requiring full alertness, such as driving or operating heavy machinery.


Q: Can I drink coffee while taking Canicol?

A: Official administration guidelines state that the oral form of Canicol may be taken with or without food. There are generally no specific restrictions on consuming non-alcoholic beverages like coffee noted in the administration section of the core regulatory summaries.


Q: Do I need to change my diet while on Canicol?

A: The official administration guidelines state that the oral form of Canicol may be taken with or without food. There are no consistently stated high-level requirements in regulatory summaries that necessitate broad dietary adjustments.


Q: How long do most people stay on Canicol?

A: Official usage dictates that Canicol is administered in short-course or intermittent regimens. The duration of treatment is limited to the short-term course of the infection, as defined in the official prescribing information.


Q: Is it normal to feel a bit nauseous when starting Canicol?

A: Official safety documentation classifies nausea as a common or uncommon side effect of Canicol. Gastrointestinal issues such as nausea, vomiting, and diarrhea are among the documented adverse reactions that may be experienced during the course of treatment.


Q: Do older adults react differently to Canicol?

A: Official restrictions for Canicol include specific caution for patients with renal impairment. Because reduced kidney function can be more common in older adults, this conditional use is noted as requiring dose adjustments.


Q: Does Canicol change how other medications are absorbed?

A: Official regulatory documents indicate that Canicol may affect the plasma levels and exposure of certain co-administered medications. For example, the medicine can increase the exposure of hormonal components in certain oral contraceptives and may affect Digoxin levels.


Q: Why did my friend say they felt dizzy on Canicol?

A: Dizziness is an adverse reaction that has been noted in the official safety documentation for the active ingredient in Canicol, Thiamphenicol. This effect is sometimes associated with nervous system issues that may be experienced by some patients.


Q: Does taking Canicol affect the results of blood tests?

A: Official regulatory documents require mandatory periodic blood examinations during any prolonged course of Canicol. This is due to the medicine's documented association with potential Blood and lymphatic system disorders, such as bone marrow suppression.


Q: Is Canicol a common medicine or a new one?

A: Canicol (Thiamphenicol) is described as a semisynthetic derivative of the classic antibiotic chloramphenicol, which has been in use for many years. Research evidence notes that many of the trials examining its use are of a historical design, indicating the medicine and its class are not new.


Q: What kind of medical professional usually prescribes Canicol?

A: Canicol is classified as a prescription-only drug and an antimicrobial agent intended for managing bacterial infections. The prescribing of Canicol is limited to licensed healthcare professionals, such as a doctor or other qualified prescriber.


Q: Are there certain foods I should avoid while on Canicol?

A: Official administration guidelines state that the oral form of Canicol may be taken with or without food. There are no specific foods listed in the regulatory summaries as being prohibited during the course of treatment.


Q: Is Canicol approved for children?

A: Official eligibility documentation generally approves the use of Canicol for adults and older children. However, its use is specifically restricted or not recommended for the youngest populations, including premature infants and newborn babies (under four weeks).


Q: Do I need a special monitoring while using Canicol?

A: Official regulatory documents mandate periodic blood examinations for any prolonged course of treatment due to safety concerns. Additionally, patients with non-severe renal impairment require mandatory dose adjustments and monitoring of kidney function.


Q: What is the typical age range of people prescribed Canicol?

A: The official eligibility documentation approves the use of Canicol for adults and older children. Use is restricted or not recommended for premature infants and newborn babies, which defines the general approved age range for the medicine.


Q: Does Canicol cause changes to heart rhythm?

A: Official regulatory documents require appropriate monitoring of Digoxin plasma levels upon initiation of Canicol. This is because the two medicines, when co-administered, may affect each other’s activity, and Digoxin is often used to manage heart conditions.


Q: Can I take Canicol if I have a history of allergies?

A: Canicol is strictly contraindicated for individuals with a known hypersensitivity (allergic reaction) to Thiamphenicol or to any other medicine belonging to the Amphenicol class.


How should Canicol be stored and disposed of?

Canicol (Thiamphenicol) must be stored strictly according to its official labeling to maintain stability. The product is required to be stored at Controlled Room Temperature (20 C to 25 C) in a dry, well-ventilated area, protected from direct sunlight. Liquid formulations must not be frozen.

Stability and Handling

Storage rules require that the container be kept tightly closed and out of the sight and reach of children. After opening, undiluted solutions must be refrigerated and discarded after 96 hours. Dilutions must be used immediately, typically within one hour of preparation.

Disposal Instructions

Expired or unused Canicol must be disposed of in accordance with local and national regulations for pharmaceutical waste. It is mandatory not to allow the product to enter drains, sewers, or waterways.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Canicol found in:

A-Z Index: